KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney disease (CKD).
Epistemonikos ID: ef1c9d03c5a6ec7c666ce26ec0f280675e0c4913
First added on: May 21, 2024